A holistic approach to training a new generation of scientists in marine biodiscovery

Fonte Standard Gras
Identifiant

Unité de recherche

SEFRI

Numéro de projet

22.00380

Titre du projet

A holistic approach to training a new generation of scientists in marine biodiscovery

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Résumé des résultats (Abstract) (Anglais)	The HOTBIO consortium will train a new generation of early-stage scientists to take marine microbial natural products from the seabed to the bedside. They will be involved in every stage of the pipeline from microbial isolation through compound purification and identification to making analogues with desirable drug-like properties. They will gain associated skills in access and benefit sharing, intellectual property and entrepreneurship. Students graduating from HOTBIO will be in a unique position to enter a challenging labour market as they will have received multidisciplinary training at world leading research groups in academia as well as at industry partners. Mentorship will be provided by industrial scientists and recent graduates from the MSCA ITN MarPipe. The HOTBIO consortium consists of eight beneficiaries from seven European countries, including two members from non-academic sectors, that will host ten PhD students. Three more PhD students hosted by two Swiss associated partners will be funded by the Swiss State Secretariat for Education, Research and Innovation. In addition to secondments at the partners in Europe, students will also get the opportunity to do secondments in low-tomiddle income countries (LMICs) in Africa and Asia to get a deeper understanding of how modern research can be done in resourcelimited setting. HOTBIO expands a conventional marine biodiscovery pipeline by including computer aided drug design (CADD), chemical synthesis of optimized compounds (i.e. medicinal chemistry), target deconvolution and extensive ADMET profiling. This will advance the bioactive microbial secondary metabolites to the later stages of preclinical development, and it will also inform the decisions and priorities of what kind of compounds that should be targeted in the initial phase of the drug discovery process. The downstream development will include hit compounds from earlier projects.

Catégorie

Texte

Résumé des résultats (Abstract)
(Anglais)

The HOTBIO consortium will train a new generation of early-stage scientists to take marine microbial natural products from the seabed to the bedside. They will be involved in every stage of the pipeline from microbial isolation through compound purification and identification to making analogues with desirable drug-like properties. They will gain associated skills in access and benefit sharing, intellectual property and entrepreneurship. Students graduating from HOTBIO will be in a unique position to enter a challenging labour market as they will have received multidisciplinary training at world leading research groups in academia as well as at industry partners. Mentorship will be provided by industrial scientists and recent graduates from the MSCA ITN MarPipe. The HOTBIO consortium consists of eight beneficiaries from seven European countries, including two members from non-academic sectors, that will host ten PhD students. Three more PhD students hosted by two Swiss associated partners will be funded by the Swiss State Secretariat for Education, Research and Innovation. In addition to secondments at the partners in Europe, students will also get the opportunity to do secondments in low-tomiddle income countries (LMICs) in Africa and Asia to get a deeper understanding of how modern research can be done in resourcelimited setting. HOTBIO expands a conventional marine biodiscovery pipeline by including computer aided drug design (CADD), chemical synthesis of optimized compounds (i.e. medicinal chemistry), target deconvolution and extensive ADMET profiling. This will advance the bioactive microbial secondary metabolites to the later stages of preclinical development, and it will also inform the decisions and priorities of what kind of compounds that should be targeted in the initial phase of the drug discovery process. The downstream development will include hit compounds from earlier projects.